Fundraising Fox
/Companies
Sign in

Sarepta Therapeutics

Cambridge, US · 2 known investors

Find your way into Sarepta Therapeutics

53 people in our graph share verified history with the Sarepta Therapeutics team — schools, employers, funds. One of them is your warm intro.

Mike Tysonunlockedknows DOUGLAS S. INGRAM · together at Allergan, inc (overlapped)
×5knows the team · via Sarepta Therapeutics
×6knows the team · via Gibson, Dunn & Crutcher LLP

Sarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions. The company also runs an investigator-initiated studies program that funds independent clinical and non-clinical research in its therapeutic areas.

BiotechHealthtech

Founders & leadership

WC
WILLIAM CIAMBRONEExecutive
DSDOUGLAS S. INGRAM
DOUGLAS S. INGRAMCEO and PresidentDouglas S. Ingram served as President of Allergan until its 2015 acquisition by Actavis, and subsequently as CEO of Chase Pharmaceuticals, a clinical-stage biopharmaceutical company developing treatments for neurodegenerative disorders, before joining Sarepta Therapeutics as CEO in 2017.
DT
DAVID TYRONNE HOWTONExecutive
SM
SANDESH MAHATMEExecutive
GO
GILMORE O'NEILLExecutive
ACALEXANDER CUMBO
ALEXANDER CUMBOExecutive
RJ
RICHARD J. BARRYNamed on SEC filing
MW
MICHAEL W. BONNEYNamed on SEC filing

Board

HW
HANS WIGZELLBoard director
CN
CLAUDE NICAISEBoard director
MA
MARY ANN GRAYBoard director
MK
M. KATHLEEN BEHRENSBoard director

Investors · 2

Roche Venture Fundlisted by Roche Venture FundBasel · $648K – $3.2M

How we know: Roche Venture Fund's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$430.5M disclosed across 2 rounds · 2019–2020

▶$400MraisedFeb 2020 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • MICHAEL W. BONNEYDirector
  • MARY ANN GRAYDirector
  • CLAUDE NICAISEDirector
  • HANS WIGZELLDirector
  • JOHN C. MARTINDirector
  • DOUGLAS S. INGRAMExecutive Officer, Director
  • ALEXANDER CUMBOExecutive Officer
  • DAVID TYRONNE HOWTONExecutive Officer
  • SANDESH MAHATMEExecutive Officer
  • GILMORE O'NEILLExecutive Officer
  • WILLIAM CIAMBRONEExecutive Officer
  • M. KATHLEEN BEHRENSDirector
  • RICHARD J. BARRYDirector
Offering amount
$400M
Amount sold
$400M
First sale
Feb 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30.5MraisedNov 2019 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • WILLIAM CIAMBRONEExecutive Officer
  • HANS WIGZELLDirector
  • CLAUDE NICAISEDirector
  • DOUGLAS S. INGRAMExecutive Officer, Director
  • DAVID TYRONNE HOWTONExecutive Officer
  • MARY ANN GRAYDirector
  • SANDESH MAHATMEExecutive Officer
  • GILMORE O'NEILLExecutive Officer
  • M. KATHLEEN BEHRENSDirector
  • RICHARD J. BARRYDirector
  • MICHAEL W. BONNEYDirector
  • ALEXANDER CUMBOExecutive Officer
Offering amount
$30.5M
Amount sold
$30.5M
First sale
Nov 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Seeking Alpha140 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.

Companies competing with Sarepta Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Acquisitions · 1

Early investors' stakes continue via these deals
Myonexus Therapeutics

Myonexus Therapeutics was a Columbus, Ohio biotech spun out of Nationwide Children's Hospital developing AAV-based gene therapies to correct genetic defects causing limb-girdle muscular dystrophies.

Frequently asked questions

What does Sarepta Therapeutics do?
Sarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions. The company also runs an investigator-initiated studies program that funds independent clinical and non-clinical research in its therapeutic areas.
Who are Sarepta Therapeutics's investors?
Sarepta Therapeutics's investors include Avoro Capital Advisors, Roche Venture Fund.
How much funding has Sarepta Therapeutics raised?
Sarepta Therapeutics has disclosed $430.5M raised across 2 rounds.
Where is Sarepta Therapeutics headquartered?
Sarepta Therapeutics is headquartered in Cambridge, US.